Objectives: Previously, one randomized control trial (TAX327) revealed the efficacy of docetaxelbased chemotherapy combined with prednisone. On the other hand, several studies showed a high prostate specific antigen (PSA) response with low-dose dexamethasone in castration-resistant prostate cancer (CRPC) patients. The objective of this study was to evaluate the efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone in CRPC patients. Materials and methods: This study was a single-arm multi-institutional phase II trial. Patients received 75 mg/m 2 of docetaxel, and 0.5 mg of dexamethasone orally twice a day continuing throughout the treatment period. Treatment was planned for 10 cycles, and continued for at least four cycles depending on the observation of PSA flare. The primary endpoint was PSA response defined as a reduction from baseline of at least 50% that continued for at least 3 weeks. Secondary endpoints were safety, PSA flare, time to PSA failure and adherence rate to protocol treatment (10 cycles). Results: Between January 2011 and February 2014, a total of 76 chemotherapy-naïve CRPC patients were enrolled. Seventy-five patients received docetaxel-based chemotherapy combined with dexamethasone. The median age and PSA level at enrollment were 71 years (53-85) and 23.2 ng/mL (2.9-852), respectively. PSA response rate was 76.8% (90% confidence interval (CI): 66.9-84.9). Of all patients, 30 patients completed 10 cycles of chemotherapy (40%). The incidence rate of PSA flare was 10.7% (eight patients). The median time to PSA failure was 369 days (95% CI: 245-369). The most frequently observed adverse event was hematotoxicity (neutropenia of G2 or greater: 100%).
Introduction
Docetaxel-based chemotherapy has been introduced for castrationresistant prostate cancer (CRPC) all across the world. Two randomized trials (Tax327 and SWOG9916) revealed a significant effect on the prognosis for overall survival (1, 2) . Prednisone (10 mg daily) was used for a balanced comparison arm with mitoxantrone in Tax 327. The prescribed dose of docetaxel was 75 mg/m 2 in the Tax327 trial (1), a dose that has been approved in western countries. In Japan, a phase II study of docetaxel-based chemotherapy with 70 mg/m 2 plus oral prednisolone 5 mg twice daily was conducted (3) . However, the approved dose of docetaxel is 75 mg/m 2 . There have been no studies to confirm the efficacy and safety of the 75 mg/m 2 dose in Japanese patients.
On the other hand, low-dose use of dexamethasone has been reported to provide meaningful cancer control (4) . Nishimura et al. reported that 62% of patients showed a decline in PSA of more than 50%, and 51% of patients achieved a decline in PSA of more than 75%. A recent randomized control trial (RCT) also confirmed significant efficacy of low-dose use of dexamethasone for CRPC patients compared with the use of prednisolone (5) .
It has been a question whether combination therapy with docetaxel (75 mg/m 2 ) and dexamethasone (1 mg) has confirmed efficacy and similar safety in CRPC patients compared with the standard therapy of docetaxel (75 mg/m 2 ) and prednisolone (10 mg) or not. Against this background, a prospective phase II trial was conducted to clarify the efficacy and safety of docetaxel-based chemotherapy combined with low-dose dexamethasone in CRPC patients.
Methods and materials

Study design and patients
This was a multicenter, single-arm, phase II trial (UMIN000004096) in both non-metastatic and metastatic CRPC patients organized by The Japan-Multinational Trial Organization (JMTO). Eligible patients had histologically confirmed prostate adenocarcinoma, confirmed CRPC and were receiving androgen-deprivation therapy (surgical or medical). Patients required three consecutive increases in PSA from the reference level (2 ng/mL or more) at intervals of at least 1 week before enrollment. Previous treatment (chlormadinone acetate or flutamide) had to be stopped for at least 4 weeks to confirm antiandrogen withdrawal syndrome (6 weeks for bicalutamide). Eligible patients had a performance status (Eastern Cooperative Oncology Group) of 0-1, no prior treatment with cytotoxic agents (including estramustine) and/or molecularly targeted therapy, a testosterone level of 50 ng/dL or less, and no other serious medical conditions. An interval of at least 4 weeks had to have elapsed between prior surgery, high intensity focused ultrasound and radiotherapy (limited to no more than 25% of the bone marrow, whole pelvis radiation or permanent brachytherapy). Laboratory criteria for eligibility were as follows: neutrophil count of at least 1500 per cubic millimeter, leukocyte count of at least 3000 per cubic millimeter, hemoglobin of at least 9.0 g per deciliter, platelet count of at least 75 000 per cubic millimeter, serum alanine aminotransferase and aspartate aminotransferase levels of not more than 2.5 times the upper limit of the normal range for each institution, a serum creatinine level of not more than 1.5 times the upper limit of the normal range, and a total bilirubin level below the upper limit of the normal range. Other ineligible criteria included peripheral motor and sensory neuropathy assessed to be grade 2 or higher according to the National Cancer Institute Common Toxicity Criteria Adverse Events version 4.0 (NCI-CTCAE Ver.4.0), hypersensitivity to the study drugs or formulation components, interstitial pneumonitis or pulmonary fibrosis, active infection, secondary active malignancy or other serious medical conditions.
The study protocol was approved by the institutional review board at JMTO and each participating institution, and written informed consent was obtained from all patients.
Treatment
Patients received 75 mg/m 2 of docetaxel as an intravenous infusion over more than an hour on Day 1, every 3 weeks and 0.5 mg of dexamethasone orally twice a day starting on Day 1 and continuing throughout the treatment period. Treatment was planned for 10 cycles, and continued for at least four cycles if PSA flare was observed.
The following criteria had to be met for patients to start the subsequent cycle: neutrophil count of at least 1500 per cubic millimeter, platelet count of at least 75 000 per cubic millimeter, serum alanine aminotransferase and aspartate aminotransferase levels of not more than 2.5 times the upper limit of the normal range for each institution, and a total bilirubin level below the upper limit of the normal range. Patients were withdrawn from the study if toxicities persisted until 6 weeks from the previous start day.
The dose of docetaxel was reduced by 10 mg/m 2 in the subsequent cycle if any of the following criteria were met: bleeding or platelet transfusion due to thrombocytopenia of grade 3 or higher, peripheral motor and sensory neuropathy of grade 2 or higher, nonhematological toxicities of grade 3 or higher including hyperglycemia, hypertension, nausea, vomiting, anorexia, fatigue or allergic reactions, or any other toxicities requiring dose reduction as judged by the attending physician. The dose reduction (0.5 mg per day) or cessation of dexamethasone was permitted if the following adverse events were seen: gastric ulcer, posterior subcapsular cataract, glaucoma, infection or any other toxicities requiring dose reduction or cessation as judged by the attending physician.
Prophylactic or therapeutic use of granulocyto colony-stimulating factor (G-CSF) was permitted and the use of bisphosphonates was also permitted for bone metastasis.
Assessments
The primary endpoint was PSA response defined as a PSA decline of 50% or more that was maintained for at least 3 weeks. Serum PSA was measured every 3 weeks. In patients with a PSA response, PSA progression was defined as an increase of at least 25% from the nadir (and a value of at least 2 ng/mL) and confirmation after 3 weeks or later. In patients without a PSA response, PSA progression was defined as an increase from the nadir of at least 25% (and at least 2 ng/mL) at four cycles.
Secondary endpoints were as follows: safety (adverse events) according to NCI-CTCAE ver.4.0, PSA flare defined as a transient increase in PSA for the first four cycles, time to PSA failure, and adherence rate to protocol treatment (10 cycles).
Statistical analysis
The primary objective was to compare the efficacy of PSA response in the Japanese phase II trial with docetaxel of 70 mg/m 2 with orally prednisolone of 10 mg a day (PSA response: 44.4%; 95% confidence interval (CI, 27.9-61.9%)) under an acceptable safety profile (3). The threshold PSA response rate was estimated to be 30%. The expected PSA response rate for this therapy was estimated to be 45% from the previous trial (3) . Assuming that the one-sided type I error was 5% and the power was 80%, the required sample size was calculated to be 72, based on the exact binomial test. The planned sample size was set at 75, taking into consideration that approximately 5% of patients are ineligible. The time to PSA failure curves were estimated using the Kaplan-Meier method. All statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Seventy-six patients were enrolled between February 2011 and February 2014. Seventy-five patients received docetaxel-based chemotherapy combined with dexamethasone, because one patient was withdrawn before starting treatment based on the ineligibility criteria. Two patients who were ineligible for previous treatment and four patients with protocol deviations of the enrollment procedure were excluded from the efficacy analysis. Finally, 75 patients were eligible for safety analysis and 69 patients for efficacy analysis. The median follow-up period was 187 days (range: 17-369 days). The median age and PSA value at enrollment were 71 years (range: 53-85 years) and 23.2 ng/mL (range: 2.9-852.0 ng/mL), respectively. The patients' characteristics are shown in Table 1 . Most patients (68.0%) showed a high Gleason score (8-10) at diagnosis. Fifty-three patients were categorized as T3-4 (70.7%), 50.7% showed nodal metastases and 77.3% were M1 at diagnosis. The median number of docetaxel administration and median treatment period were 8 (range: 1-10) and 162 days (range: 1-334 days), respectively. Eighteen patients (24%) needed dose reduction. The mean relative dose intensity was 97.5% (median: 100%). On the other hand, the median dosing period of dexamethasone administration was 182 days (range: 14-369 days). Five patients (6.7%) needed dose reduction. The mean relative dose intensity was 99.6% (median: 100%).
Primary endpoint
The PSA response rate (50% reduction or more) in all patients (69 patients) was 76.8% (90% CI: 66.9-84.9, 95% CI: 65.1-86.1) ( Table 2 ). This response rate was significantly higher than the prespecified threshold (30%) and that in a Japanese phase II trial (PSA response: 44.4%, 95%CI, 27.9-61.9%) (3). The PSA response rate of patients without metastases (16 patients) was 81.3% (90% CI: 58.3-94.7, 95% CI: 54.4-96.0), while that of patients with metastases (53 patients) was 75.5% (90% CI: 63.9-84.8, 95% CI: 61.7-86.2). The median PSA decline rate of responders was 92.8%. Sixteen patients (23.2%) were categorized as non-responders. A waterfall plot of PSA decline is shown in Fig. 1 .
Secondary endpoints
Regarding PSA flare, eight patients (10.7%) showed a transient increase during the first four cycles of chemotherapy. Figure 2 shows a Kaplan-Meier curve of time to PSA failure. The median time to PSA failure was 369 days (95% CI: 245-369 days). The adherence rate to the protocol treatment was 40% (30/75).
Safety analysis was carried out in 75 patients, 45 patients discontinued the protocol treatment due to adverse events (91%) and progressive disease (9%). Seventy-three patients (97%) out of all patients showed any adverse events of grade 3 or higher. The most frequently observed adverse event of grade 3 or higher was neutropenia (grade 3: 17.3%, grade 4: 80%) ( Table 3) . Three patients (4%) suffered from interstitial pneumonia of grade 3 or higher (two patients: grade 3; one patient: grade 4). We experienced two patients with treatment-related death (2.7%) during the follow-up period. One cause of death was upper gastrointestinal bleeding, and the other was aspiration pneumonia.
Discussion
The main objective of this study was to confirm equivalent efficacy and safety of docetaxel-based chemotherapy (75 mg/m 2 ) with a low dose of dexamethasone (1 mg) compared with the Japanese phase II trial (3). The PSA response of the Japanese phase II trial was 44.4% (95% CI: 27.9-61.9%). The PSA response rate of TAX 327 (a phase III trial) was 45% (95% CI: 40-51%) in the arm receiving 75 mg/m 2 docetaxel every 3 weeks and 5 mg prednisone twice a day (1).
The present study achieved an exceptional PSA response (76.8%) compared with the Japanese phase II trial (44.4%) and TAX 327 (45%). It is noteworthy that the lower limit of 95% CI in the present study was higher than the upper limit of the Japanese phase II trial and the TAX327 phase III trial. The waterfall-plot of PSA change also shows a median decline of 93% (Fig. 1) . The prescribed dose of docetaxel in the present study is higher than in the Japanese phase II trial (70 vs 75 mg/m 2 ), but the same as on the TAX327 phase III trial (75 mg/m 2 ). Although an influence of the different dose of docetaxel cannot be denied, the significant difference in PSA response is probably derived from the different type of corticosteroid used. Previous reports showed a relative higher PSA response rate (50-62%) with single use of low-dose dexamethasone in CRPC patients (4, 6, 7) . On the other hand, single use of prednisolone in CRPC patients achieved a lower PSA response (8) (9) (10) (11) . The mechanism of corticosteroid action in CRPC has been considered as inhibition of the pituitary production of adrenocorticotropic hormone (ACTH). Dexamethasone has a longer half-time than prednisolone, leading to higher anticancer activity. Nishimura et al. reported that dexamethasone reduced secretion of interleukin-6 in the prostate cancer cell line, DU145 (12) . Yano et al. showed that dexamethasone had an antiangiogenic effect on prostate cancer cell lines (13) .
The protocol of this trial defined the maximum number of cycles of protocol treatment as 10 cycles. One of the secondary endpoints of this study was adherence to the protocol treatment (10 cycles). Thirty out of 75 patients (40%) completed 10 cycles of chemotherapy. The median number of this trial was 8 cycles. On the other hand, in the Japanese phase II trial, the median cycle was 9. The relative dose intensity of docetaxel was 97.5% in this trial, whereas that of Japanese phase II trial was 88% (3). Concerning the difference in docetaxel dose (75 vs 70 mg/m 2 ), the present trial revealed the possibility to prescribe 75 mg/m 2 of docetaxel for Japanese men.
Previous studies reported a transient PSA rise (11-18%) during chemotherapy in CRPC patients (14) (15) (16) . Usually, a PSA flare does not have an impact on oncological outcome and survival (14, 17) . In this trial, eight patients (10.7%) showed a transient PSA increase (PSA flare). The incident rate of PSA flare was compatible with that in previous reports (14) (15) (16) .
The incident rate of adverse events is different between western patients and Japanese patients. For example, 32% of patients in TAX 327 (docetaxel every 3 weeks arm) showed grade 3 or 4 of neutropenia (1) . On the other hand, 93% of patients showed grade 3 or 4 neutropenia in the Japanese phase II trial (3) . In the present trial, 97% of patients showed grade 3 or 4 neutropenia. We experienced two patients with treatment-related death (2.7%). One was due to upper gastrointestinal bleeding, the other to aspiration pneumonia. On the other hand, the incident rate of treatment-related deaths of both the TAX 327 and SWOG 9916 trials were 0.3% and 2.4%, respectively (1,2).
The Kaplan-Meier curve showed a median time of 369 days to PSA failure (Fig. 2) . Unfortunately, the last follow-up period was defined as 3 weeks after the last administration of docetaxel. Most patients did not meet the criteria of PSA failure at the last follow-up.
The present trial has several limitations. Firstly, the primary endpoint was the PSA response. We did not evaluate radiographic progression. Secondly, this is a single-arm trial with a small sample size. To confirm the excellent PSA response, a randomized controlled trial is necessary. Thirdly, it is inappropriate to compare the results with the Japanese phase II trial because of the difference of patient characteristics. The present trial included non-metastatic CRPC patients (22.7%), whereas all patients in the Japanese phase II trial were metastatic. Fourthly, the overall survival is unknown due to the short follow-up period. Under these limitations, an additional follow-up study is underway to confirm radiographic progression free survival, overall survival, the profile of additional treatments and late adverse events.
Conclusions
The present study showed a novel PSA response in patients who received docetaxel-based chemotherapy combined with low-dose dexamethasone compared with previous reports. Most patients tolerated the protocol schedule, whereas hematotoxicity was often observed. 
